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Abstract
Middle segment pancreatectomy (MSP) is a new operation where the advantages of parenchymal preservation are
counterbalanced by a high postoperative complication rate and unease among surgeons with adopting a new technique.
This study reviews our experience incorporating MSP into our clinical practice focusing on the initial 34 consecutive
patients operated on by one surgeon at a single institution between 1998 and 2007. Patients were divided into early (initial
17 operations) and late (subsequent 17 operations) groups for analysis. Thirty-one reconstructions were by Roux-en-y
pancreaticojejunostomy and three were by pancreaticogastrostomy. Using multiple linear regression and logistic regression,
we found no significant differences in performance outcomes (operative time, blood loss, tumor size, margin negative
resection rate, pancreatic fistula rate, hospital length of stay, postoperative complications, and hospital readmission rate)
between our early and late experience even after adjusting for potential confounding variables (patient demographics, co-
morbidities, neoplasm, pancreatitis). The pancreatic fistula rate in this series was 29.4% (10/34) and they were all
International Study Group on Pancreatic Fistula (ISGPF) Grade A (60%) or B (40%). In summary, MSP is an operation
with a flat learning curve and acceptable morbidity rate that can be safely incorporated as a parenchymal preserving option
by pancreatic surgeons in their clinical practice.
Key Words: central pancreatectomy, pancreaticojejunostomy, focal chronic pancreatitis, pancreatic fistula, parenchymal
sparing pancreatectomy
Introduction
Operations for benign lesions of the pancreatic neck
and body have always posed an interesting dilemma.
Standard anatomic resections such as pancreatico-
duodenectomy (PD) or extended distal pancreatect-
omy (EDP) remove significantly more tissue than
necessary to achieve negative surgical margins, while
enucleation is limited to small (52 cm) superficial
lesions not involving the pancreatic duct [1,2]. Middle
segment pancreatectomy (MSP), or the Dagradi-
Serio-Iacono operation, is a new procedure tailored
to remove the area of abnormality while preserving
functioning pancreatic parenchyma [3].
Indications for this operation include benign and
premalignant conditions as well as solitary metastases
to the pancreas (Table I) [3]. Benefits of MSP include a
reduction in long-term pancreatic endocrine and exo-
crine insufficiency, maintenance of upper gastrointest-
inal tract continuity, and splenic preservation [4,5].
These advantages are counterbalanced by a reportedly
higher perioperative complication rate coupled with
unease among surgeons in adopting a new operation
[1]. The higher complication rate noted with this
procedure is due to the fact that many patients who
are candidates have a normal pancreas and the opera-
tion has two potential sources for pancreatic fistula: the
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oversewn proximal pancreatic remnant and the distal
pancreatic enteric anastomosis (see Figure 1) [5,6].
This study describes our initial experience with
MSP. It was designed to review the introduction of
this procedure into our clinical practice and analyze
our results as they relate to defined performance
outcomes. This information will aid in determining
if a surgical learning curve exists for this procedure,
and whether it can be safely implemented into clinical
practice.
Methods
We performed an analysis of our prospective pancrea-
tic resection database and cross referenced this with
the operating room case database to identify all
patients undergoing MSP at Indiana University Med-
ical Center between November 1, 1998 and July 1,
2007. Prior approval for this investigation was ob-
tained through the IUPUI Institutional Review Board
(0707-80) and patient records were retrospectively
reviewed. To analyze performance outcomes asso-
ciated with the experience of learning this operation,
we identified 34 consecutive patients operated on by a
single surgeon Thomas John Howard (TJH). These
patients were then divided into early (initial 17
operations) and late (subsequent 17 operations)
groups. In all cases, the choice of operation was
made by the staff surgeon based on patient character-
istics and lesion specific variables. We analyzed patient
demographics, preoperative co-morbidities, indica-
tions for operation, lesion specific variables, intrao-
perative variables, postoperative complication rates,
and hospital length of stays. Postoperative complica-
tions were classified by the grading system of DeOli-
veira [7] and pancreatic fistulas were defined by the
International Study Group on Pancreatic Fistula
(ISGPF) guidelines [8].
Continuous variables were summarized by mean
and standard deviation and categorical variables were
summarized by frequency and percentage. Two-sam-
ple t-test and Fisher’s exact test were used to compare
Figure 1. Middle segment pancreatectomy with roux-en-y pancreaticojejunostomy reconstruction.
Table I. Indications for middle segment pancreatectomy (3).
 Tumors localized to the neck or proximal body of the pancreas
where at least 5 cm of distal pancreatic remnant remains after
obtaining adequate surgical margins.
 Tumor size between 2 cm and 5 cm where enucleation entails a
high risk of injury to the main pancreatic duct (Wirsung’s duct).
 Smaller tumors deeply embedded in the gland and not eligible
for enucleation (i.e. functioning neuroendocrine tumors).
 Benign or low-grade malignant tumors (serous and mucinous
cystadenomas, neuroendocrine tumors, solid pseudopapillary
tumors, non-invasive side branch intraductal papillary
mucinous neoplasms) in which a conservative resection can be
carried out with free margins.
 Benign cystic lesions (lymphoepithelial, dermoid, and hydatid
cysts) not suitable for enucleation.
 Solitary metastases to the pancreatic neck and metastatic
pancreatic neuroendocrine tumors undergoing multimodality
treatment.
 Focal chronic pancreatitis with isolated and short stenosis of
Wirsung’s duct.
492 H. Lavu et al.
continuous and categorical variables, respectively.
Wilcoxon rank-sum test was also conducted to
compare continuous outcomes. Multiple linear re-
gression and logistic regression were used to relate
dependent variables with primary independent vari-
ables by adjusting for potential confounding factors.
All analysis were conducted using SAS 9.1 (SAS, Inc.,
Cary, NC).
Results
Over the nine year study period, there were 1332
pancreatic resections performed at the Indiana Uni-
versity Medical Center, of which 38 were MSP
(2.9%) done by four surgeons. A single surgeon
(TJH) completed 34 of these operations. Of these
thirty-four consecutive resections, thirty-one recon-
structions were by pancreaticojejunostomy and three
were by pancreaticogastrostomy. There were 65%
females with a mean age of 49 years (916 years)
and a range from 19 to 75 years (Table II). Pre-
operative diabetes mellitus was present in 15% of the
group while 18% had preoperative pancreatic insuffi-
ciency. Significant preoperative co-morbidities were
found in 47% of patients including hypertension,
diabetes, coronary artery disease, stroke, chronic
obstructive pulmonary disease, and hepatitis. Indica-
tions for operation were focal chronic pancreatitis in
24 patients and pancreatic neoplasm in 10 patients.
Of the pancreatic neoplasms, final surgical pathology
identified: Intraductal papillary mucinous neoplasm
(IPMN) five, solid pseudopapillary tumor three,
adenocarcinoma one, and serous macrocystic ade-
noma one. The mean tumor size in the neoplasm
group was 2.5 cm (91.6 cm), ranging from 0.7 cm
to 4.8 cm. Mean operative time was 244.7 minutes
(958 min) and the mean estimated blood loss (EBL)
was 720.9 milliliters (91143.7 ml). Mean length of
hospital stay was 9.2 days (94.8 days) and the
hospital readmission rate was 12%. Postoperative
morbidity rate was 47.1%. Using the classification
system described by DeOliveira et al. [7], complica-
tions were graded as: No Complication 53%, Grade I
9%, Grade II 21%, Grade IIIa 18%. There were no
Grade IV (life threatening complication) or V (death)
complications. The pancreatic fistula rate in this series
was 29.4% (10/34) and they were all ISGPF Grade A
(60%) or B (40%). While there was a trend toward
increased EBL early in our experience, these results
can be explained by the higher percentage of patients
with focal chronic pancreatitis (88.2% vs. 52.9%) in
this group.
When patients were stratified and analyzed by the
type of pancreatic disease (either neoplasm or focal
chronic pancreatitis) that initiated the operation, we
again found no significant differences in the perfor-
mance outcomes measured, namely, operative time,
EBL, pancreatic fistula rate, length of hospital stay,
margin negative resection rate, tumor size, hospital
readmission rate, or number of postoperative compli-
cations (Table III). Because these results were strati-
fied by disease type, we chose to divide the 10
neoplasm patients into five early and five late;
similarly the 24 patients with focal chronic pancrea-
titis were divided into 12 early resections and 12 late.
While a higher percentage of female patients had
neoplasms (100% vs. 50%, p0.01), this variable was
not statistically significant. Overall, we identified a
higher postoperative hospital readmission rate in the
neoplasm group compared to the chronic focal
pancreatitis group (30% vs. 4%). This variable was
likely influenced by the higher pancreatic fistula
rate in the neoplasm group (40% vs. 25%), but
within each disease subset, there were no significant
Table II. Clinical characteristics and performance outcomes for ‘‘early’’ and ‘‘late’’ patients who underwent middle segment pancreatec-
tomy (MSP).
Total (N34) Early (N17) Late (N17) p$
Clinical characteristics
% Female 22 (64.7%) 9 (52.9%) 13 (76.5%) 0.28
Age (years) 49.4 (15.5) 49.1 (14.1) 49.8 (17.3) 0.90
Pancreatitis 24 (70.6%) 15 (88.2%) 9 (52.9%) 0.06
Neoplasms (%) 10 (29.4%) 2 (%11.8) 8 (47.1%) 0.06
Co-morbidities 16 (47.1%) 7 (41.2%) 9 (52.9%) 0.73
Interventional radiology* 2 (5.9%) 0 2 (11.8%) 0.48
Performance outcomes
Operative time (min) 244.7 (58.1) 251.6 (44.4) 237.8 (70.0) 0.50
Blood loss (ml) 720.9 (1143.7) 729.4 (627.5) 712.4 (1517.8) 0.06$$
Pancreatic fistula 10 (29.4%) 4 (23.5%) 6 (35.3%) 0.71
Hospital length of stay 9.2 (4.8) 9.6 (5.6) 8.7 (4.0) 0.58
Hospital readmission 4 (11.8%) 2 (11.8%) 2 (11.8%) 1
Post-operative complications 16 (47.1%) 7 (41.2%) 9 (52.4%) 0.73
*Need for interventional radiology to treat a post-operative fluid collection.
$p-values are based on two-sample t-test for continuous variables and Fisher’s exact test for binary variables.
$$p-value is based on Wilcoxon rank-sum test due to outliers. For other continuous variables, Wilcoxon rank-sum test was also conducted
and the p-values are similar to the t-test.
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differences in these complications with the level of
operative experience.
Using linear or logistic regression, we investigated
both continuous outcome variables (operative time,
EBL, hospital length of stay) and binary outcome
variables (pancreatic fistula, postoperative complica-
tions, hospital readmissions) and their rate of change
with the experience gained by each successive
operation (xth operationindependent variable)
(Table IV). We found clinically insignificant declines
in operative time (0.19), EBL (3.9), and hospital
length of stay (0.029) which changed little when
adjusting for age, co-morbidity, and disease type
(Model 2). Adjusting for age and co-morbidity in
the focal chronic pancreatitis group (Model 3) and
age, co-morbidity, and tumor size in the neoplasm
group also did not identify any significant differ-
ences.
It is possible that our sample size might not have
been sufficient to identify a potential association
between operative experience and clinical outcomes.
Nevertheless, the parameter estimates shown in
Table IV suggest that such associations, even if
they were to exist, are not likely to represent a
clinically significant change in performance.
Discussion
Benign pancreatic lesions and focal pancreatic duct
strictures are being diagnosed more frequently due
to the increased use of high resolution cross-sectional
imaging (computer tomography (CT) and magnetic
resonance cholangiopancreatography (MRCP)),
endoscopic retrograde cholangiopancreatography
(ERCP), and endoscopic ultrasonography (EUS) to
investigate upper gastrointestinal tract symptoms
[9]. Classically, lesions in the head of the pancreas
have been treated with PD while lesions in the tail of
the pancreas have been treated with distal pancrea-
tectomy. Extended versions of these operations have
been applied to resect lesions involving the neck and
proximal body of the pancreas. MSP is an operation
specifically designed to treat such lesions while
sparing normal pancreas, duodenum, spleen, and
preserving bilioenteric continuity [3]. Although por-
tions of the operation were described by Guillemin
and Bessot in 1957 and Letton and Wilson in 1959,
its adaptation to its current form and use in the
treatment of pancreatic neoplasia was first described
by Dagradi and Serio in 1984 [1,36,1114]. The
operation has been performed more commonly in
recent years but its narrow indications limit its
application to only a small fraction of all pancreatic
surgery cases. MSP accounts for less than 3% of
pancreatic resections at most high volume centers,
including our own [1,12].
This study reviews the incorporation of MSP into
our clinical practice. It focuses on the initial 34
consecutive patients operated on by a single surgeonT
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and analyzes the results in terms of early and late
cohorts. This analysis was conducted to determine
how the learning curve associated with adopting a
complex new procedure can affect patient outcomes.
Achieving competence in any new operation in-
volves the acquisition of both decision making ability
and technical skill [15]. For MSP, decision making
occurs in applying the operation to appropriate
patients, making intraoperative decisions based on
anatomic findings, ensuring a margin negative resec-
tion, and identifying and adequately treating post-
operative complications. By these metrics, we found
no significant differences between our early and late
experience. Thirty-three of 34 patients (97%) had
benign or premalignant conditions. One patient in
this series was operated on for a pancreatic duct
stricture which had negative surgical margins on
frozen section examination intraoperatively. On per-
manent histology, a T2N1M0 adenocarcinoma aris-
ing from the ductal stricture with negative surgical
margins (R0 resection) was identified. The patient
declined further surgery, underwent adjuvant che-
moradiotherapy, and developed metastatic disease
eight months postoperatively. MSP was not designed
as an oncologic operation and should not be used to
treat patients with known invasive adenocarcinoma of
the pancreas [36,1214].
Of the three patients with positive resection margins
in this series, all had side-branch IPMN with negative
margins on intraoperative frozen section. IPMN was
later identified involving small peripheral ducts at the
margin of resection on permanent histologic exam-
ination. There were no positive margins involving the
main pancreatic duct. None of these patients with a
positive postoperative margin for IPMN has devel-
oped a recurrence or undergone reoperation during
follow-up of 51, 41, and five months, respectively. In
patients with IPMN who have main duct involvement,
the possibility of intraductal extension of the lesion
and the high incidence of associated malignancy make
MSP a poor choice for resection [12]. For side branch
IPMN, intraoperative frozen section analysis of re-
sected lesions is mandatory to exclude malignancy
and ensure negative resection margins before
the pancreaticoenteric reconstruction is completed.
Non-functioning neuroendocrine tumors also present
an interesting dilemma because they are difficult to
classify as benign or malignant on either preoperative
work up or intraoperative frozen section examination
[6]. MSP in this setting carries the risk of performing
what would be considered an inadequate cancer
operation for a patient found to have a malignant
neuroendocrine neoplasm on final pathologic evalua-
tion. This situation would appear uncommon for
small neuroendocrine neoplasms (B3 cm) where in
the Crippa et al. series, there were no tumor recur-
rences found in 32 patients following MSP over a
mean five year period of follow-up [12].
When analyzing the technical skill component of
achieving competence in an operation, direct observa-
tion and grading metrics remain poorly defined and
limited to the prospective accrual of data. In a
retrospective analysis, surrogates of technical skill
which we term performance outcomes are variables
that are directly influenced by surgical technique and
can be readily measured and quantified. Technical
aspects of MSP involve: dissection of the pancreas off
of both the superior mesenteric portal venous con-
fluence and proximal splenic vein; oversewing of the
proximal (duodenal) pancreatic remnant; and con-
struction of a pancreaticoenteric anastomosis (pan-
creaticogastrostomy or pancreaticojejunostomy) to
the distal pancreatic remnant [3]. Using multiple
linear regression and logistic regression, we found
Table IV. Four regression models investigating the effect of each successive operative experience on both continuous and binary outcome
variables.
Model 1 Model 2 Model 3 Model 4
Model $ Parameter* p Parameter p Parameter p Parameter p
Continuous outcome
Operativet time (min) 0.19 0.85 1.06 0.41 2.1 0.13 0.19 0.96
Estimated blood loss (ml) 3.9 0.85 6.76 0.79 9.3 0.80 0.85 0.95
Hospital length of stay 0.029 0.73 0.03 0.74 0.11 0.35 0.15 0.61
Binary outcome
Pancreatic fistula 1.05 0.27 1.03 0.57 1.04 0.55 0.90 0.47
Post-operative complications 1.04 0.28 1.04 0.32 1.04 0.48 0.98 0.85
Hospital readmission 1.00 0.96 0.89 0.20 NA$$ NA NA NA
*For continuous outcomes, the parameter is the regression coefficient in the linear regression model; for binary outcomes, the parameter is
the estimated odds ratio in logistic regression model.
$Model 1: only include the xth time the operation is performed as the independent variable.
Model 2: adjust for age, co-morbidity and disease type.
Model 3: fit to patients with focal chronic pancreatitis, adjusting for age and co-morbidity.
Model 4: fit to patients with neoplasm, adjusting for age, tumor size and co-morbidity.
$$Data points are too sparse for maximum likelihood estimation.
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no significant differences in performance outcomes
(operative time, blood loss, tumor size, margin
negative resection rate, pancreatic fistula rate, hospital
length of stay, postoperative complications, and hos-
pital readmission rate) between our early and late
experience performing this operation (Table II), even
after adjusting for potential confounding variables
(patient demographics, co-morbidities, neoplasm,
pancreatitis) (Table III). When analyzing these patient
outcomes and their rate of change with the experience
gained from each successive operation, we again
found no significant differences (Table IV). Graphic
representation of these results is a flat regression line
which implies a flat surgical learning curve for this
operation. These findings are predictable in that the
technical skills required for MSP are used by the
experienced pancreatic surgeon in both PD and distal
pancreatectomy, two of the most commonly per-
formed pancreatic resections [16,17].
An inherent limitation of MSP is the risk of
pancreatic fistula that is higher than in standard
pancreatic resections, presumably due to the fact
that there are two cut surfaces of the pancreas to
contend with rather than just one as in PD or distal
pancreatectomy. Leakage from oversewing the duo-
denal segment would be similar to a fistula from a
distal pancreatectomy, whereas leakage from the distal
segment behaves like a pancreaticoenteric anastomo-
sis [18]. Unlike PD however, reconstruction in MSP
is performed utilizing a defunctionalized Roux-en-y
limb of jejunum. The overall pancreatic fistula rate in
this series was 29.4%, with a higher fistula rate in
patients with neoplasms (40%) than chronic pancrea-
titis (25%), presumably due to differences in pan-
creatic texture. All pancreatic fistulas in this series
were ISGPF grade A or B. Our fistula rate is similar to
the 2336% rate reported in most surgical series
[1,5,12,14], but is much higher than the 8 and
7.5% rates reported by the groups in Lyon and
Heidelberg [11,13]. These discrepancies may be
related to definitions of pancreatic fistula although it
is worth noting that in the two centers with low
pancreatic fistula rates, reoperation rates were con-
siderably higher at 12 and 5%, respectively, than in
other published series suggesting the presence of
undrained amylase-rich fluid collections (uncon-
trolled fistula) requiring operative drainage [11,13].
Our results with MSP also compare favorably to the
largest single institiution experience with distal pan-
createctomy (235 patients), where Lillemoe et al
showed a postoperative complication rate of 31%,
pancreatic fistula rate of 5%, reoperation rate of 6%,
and perioperative mortality rate of 0.9% [19]. In a
collective review of the literature of 207 patients
undergoing MSP compiled by Roggin et al., the
overall morbidity rate was 33.3% and the pancreatic
fistula rate was 22.2% [1]. Based on these data and
our own clinical experience, it appears that the
majority of controlled external pancreatic fistulae
following MSP are ISGPF grade A or B, do not
require reoperation, and can be managed successfully
using conservative measures [1,5,12,14].
Determining an individual patient’s risk of post-
operative diabetes mellitus following pancreatic resec-
tion relates to the functional capacity of the
underlying gland, the extent of resection, and the
length of postoperative observation [10]. While it
seems intuitive that the preservation of pancreatic
mass would improve long-term pancreatic endocrine
and exocrine function [20], it is clear that in most
patients with an otherwise normal pancreas, there is
an excess of functional capacity [6]. However, in
patients with chronic pancreatitis, underlying gland
dysfunction makes postoperative endocrine insuffi-
ciency more unpredictable [21,22]. Our postoperative
rate of new onset endocrine insufficiency was 5%. In a
collective review by Iacono of 296 patients following
MSP reported in the literature, the reported rate of
postoperative exocrine insufficiency was 4% and the
rate of postoperative endocrine insufficiency was 3%
[3]. MSP design also preserves the spleen, an organ
commonly removed during distal pancreatectomy
resulting in a life-long risk of overwhelming post
splenectomy sepsis and reduced immune function
[23].
Surgery for chronic pancreatitis has typically
focused on either pancreatic head resections, long-
itudinal duct decompression, or distal pancreatect-
omy. Some patients with chronic pancreatitis have
what has been termed ‘‘focal chronic pancreatitis’’
characterized by a dominant pancreatic duct stricture
in the neck or proximal body of the pancreas. This
anatomic abnormality can also be identified in symp-
tomatic patients after recovery from a bout of severe
acute pancreatitis, presumably the result of main duct
stricturing from fibrosis during the healing process
[24]. Some have argued that in patients with chronic
pancreatitis, such focal strictures are epiphenomena
and surgical treatment should instead be directed at
the pancreatic head, considered to be the ‘‘pace-
maker’’ of the disease. Despite these presumptions,
endoscopists have been successfully dilating and
stenting these strictures with good symptom resolu-
tion and improved long-term quality of life [25,26].
While MSP seems ideally suited to patients with focal
chronic pancreatitis, most series contain very few such
patients, likely due to the narrow indications (focal
stricture in the pancreatic neck without complications
involving adjacent organs, such as duodenal obstruc-
tion or common bile duct stenosis) for the application
of this operation. In a recent prospective series,
Mu¨ller et al. reported on 23 patients that under-
went MSP for focal chronic pancreatitis and found
that in a matched pair’s analysis with patients who
underwent PD or distal pancreatectomy, there were
no significant differences in terms of perioperative
morbidity or pancreatic fistula rates [13]. Careful long
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term (5 year) follow-up will be necessary to fully
evaluate the role of MSP in chronic focal pancreatitis.
Conclusion
MSP offers a tailored approach to lesions in the neck
and proximal body of the pancreas. Increasing evi-
dence suggests that gland preservation leads to lower
rates of both pancreatic endocrine and exocrine
insufficiency. Although infrequently used due to its
narrow indications, this operation can be safely
performed without a significant learning curve by
experienced pancreatic surgeons.
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